The purpose of this study is to determine whether bortezomib, cytarabine, and dexamethasone are effective in the treatment of relapsed or refractory mantle cell lymphoma after 1 to 3 lines of previous treatment.

Inclusion Criteria:

• Pathologically confirmed mantle cell lymphoma
• Relapse or progression after 1-3 lines of previous chemotherapy with or without immunologic agents
• ECOG performance status 2 or less
• Adequate hematologic, hepatic, and renal function i. White blood cells ≥ 3,000 /ul ii. Absolute neutrophil count ≥ 1,000 /ul iii. Platelets ≥ 50,000 /ul iv. Hemoglobin ≥ 9.0 g/dL v. Total bilirubin < 2 times upper limit of normal vi. AST, ALT < 2.5 times upper limit of normal vii. Serum creatinine < 1.5 times upper limit of normal

Exclusion Criteria:

• Previously treated with 4 or more lines of chemotherapy with or without immunologic agents
• Previously treated with bortezomib
• Treated with a cytarabine-containing regimen as the last line and within 6 months before registration
• Other cancer diagnosed within 5 years before registration
• Uncontrolled symptomatic CNS involvement of mantle cell lymphoma
• Uncontrolled systemic infection
• Inherited immunodeficiency disease or AIDS
• Pregnancy
• Breast-feeding
• Peripheral neuropathy of grade 3 or higher
• Other health conditions considered to be inappropriate for this trial in the primary physician's opinion

Demographics, baseline characteristics, response, survival data